Risk of Dependence on Dialysis Agents for Artificial Kidneys
First written in FY2016. 23 of 25 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
28 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「The artificial-kidney dialysis solutions that are the main products of our pharmaceutical business face intense market competition. As a leading dialysis-solution manufacturer, we are working to strengthen our market competitiveness by developing new dialysis solutions and reducing manufacturing costs, while also promoting expansion into new fields and businesses to meet emerging medical needs. However, if the market environment changes beyond expectations due to the emergence of innovative products or treatment technologies, business results may be materially affected.」
It continues to address the risks of dependence on and competition relating to the main dialysis solutions, along with measures involving new dialysis solutions, cost reductions, and new fields and businesses. - FY2024-Q3RestatedAnnual report
「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the risks of dependence on and competition relating to artificial-kidney dialysis solutions. - FY2024-Q1RestatedAnnual report
「There were no new major risks during the three months ended 30 June, and no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the risks of dependence on and competition relating to artificial-kidney dialysis solutions. - FY2023-Q3RestatedAnnual report
「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the risks of dependence on and competition relating to artificial-kidney dialysis solutions. - FY2022RestatedAnnual report
「The artificial-kidney dialysis solutions that are the main products of our pharmaceutical business face intense market competition. As a leading dialysis-solution manufacturer, we are working to strengthen our market competitiveness by developing new dialysis solutions and reducing manufacturing costs, while also promoting expansion into new fields and businesses to meet emerging medical needs. However, if the market environment changes beyond expectations due to the emergence of innovative products or treatment technologies, business results may be materially affected.」
It continues to describe dependence on the main dialysis solutions and competition risks, as well as measures involving new dialysis solutions, cost reductions, and new fields and businesses. - FY2022-Q2RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate dependence on the artificial-kidney dialysis solutions that are its main products and the possibility that intense market competition may affect business results. - FY2021ReframedAnnual report
「The artificial-kidney dialysis solutions that are the main products of our pharmaceutical business face intense market competition. As a leading dialysis-solution manufacturer, we are working to strengthen our market competitiveness by developing new dialysis solutions and reducing manufacturing costs, while also promoting expansion into new fields and businesses to meet emerging medical needs. However, if the market environment changes beyond expectations due to the emergence of innovative products or treatment technologies, business results may be materially affected.」
For the risk of dependence on dialysis solutions, it specifies measures including new dialysis solutions, cost reductions, and new fields and businesses, as well as changes in the market environment resulting from innovative products and treatment technologies. - FY2021-Q3RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate dependence on the artificial-kidney dialysis solutions that are its main products and the possibility that intense market competition may affect business results. - FY2021-Q2RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate dependence on the artificial-kidney dialysis solutions that are its main products and the possibility that intense market competition may affect business results. - FY2021-Q1RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate dependence on the artificial-kidney dialysis solutions that are its main products and the possibility that intense market competition may affect business results. - FY2020-Q3RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, significant changes in the market environment or other factors may affect our current business results.」
It continues to describe the possibility that competition and significant changes in the market environment or other factors may affect business results for its leading-market-share main dialysis solutions. - FY2020-Q2RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, significant changes in the market environment or other factors may affect our current business results.」
It continues to describe the possibility that competition with domestic and overseas companies and significant changes in the market environment or other factors may affect business results for its leading-market-share main dialysis solutions. - FY2020-Q1RestatedAnnual report
「The pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, significant changes in the market environment or other factors may affect our current business results.」
It continues to describe the possibility that competition with domestic and overseas companies and significant changes in the market environment or other factors may affect business results for its leading-market-share main dialysis solutions. - FY2019RestatedAnnual report
「The artificial-kidney dialysis solutions that are the main products of our pharmaceutical business face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, a substantial decline in revenue due to the market environment may affect business results.」
It continues to describe the possibility of lower revenue due to the market environment for its leading-market-share main dialysis solutions. - FY2019-Q3RestatedAnnual report
「Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, significant changes in the market environment or other factors may affect our current business results.」
It continues to describe the possibility that significant changes in the market environment or other factors may affect business results for its leading-market-share main dialysis solutions. - FY2019-Q2RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, significant changes in the market environment or other factors may affect our current business results.」
It continues to describe the possibility that significant changes in the market environment or other factors may affect business results for its leading-market-share main dialysis solutions. - FY2019-Q1RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, significant changes in the market environment or other factors may affect our current business results.」
It continues to describe the possibility that significant changes in the market environment may affect business results for its leading-market-share main dialysis solutions. - FY2018RestatedAnnual report
「The artificial-kidney dialysis solutions that are the main products of our pharmaceutical business face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, a substantial decline in revenue due to the market environment may affect business results.」
It continues to identify dependence on the main dialysis solutions and the possibility of lower revenue due to the market environment as risks. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter of the current fiscal year, there were no occurrences of matters concerning the business situation, accounting situation or other matters described in the quarterly report that could have a material impact on investors’ decisions, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to business and other risks, including dependence on artificial-kidney dialysis solutions. - FY2018-Q1RestatedAnnual report
「During the cumulative first quarter of the current fiscal year, there were no occurrences of matters concerning the business situation, accounting situation or other matters described in the quarterly report that could have a material impact on investors’ decisions, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to business and other risks, including dependence on artificial-kidney dialysis solutions. - FY2017RestatedAnnual report
「The artificial-kidney dialysis solutions that are the main products of our pharmaceutical business face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, a substantial decline in revenue due to the market environment may affect business results.」
It continues to identify dependence on the main dialysis solutions and the possibility of lower revenue due to the market environment as risks. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter of the current fiscal year, there were no occurrences of matters concerning the business situation, accounting situation or other matters described in the quarterly report that could have a material impact on investors’ decisions, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the risk of dependence on artificial-kidney dialysis solutions. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no occurrences of matters concerning the business situation, accounting situation or other matters described in the quarterly report that could have a material impact on investors’ decisions, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the risk of dependence on artificial-kidney dialysis solutions. - FY2017-Q1RestatedAnnual report
「During the cumulative first quarter of the current fiscal year, there were no occurrences of matters concerning the business situation, accounting situation or other matters described in the quarterly report that could have a material impact on investors’ decisions, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the risks described in the previous fiscal year. - FY2016First statedAnnual report
「The artificial-kidney dialysis solutions that are the main products of our pharmaceutical business face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, a substantial decline in revenue due to the market environment may affect business results.」
It indicates that the main dialysis solutions face intense competition and that a decline in revenue due to the market environment may affect business results.